Recently, Shandong Yingsheng, the leading domestic mass spectrometry detection enterprise, announced that it had completed nearly 100 million yuan of financing, which was jointly invested by Yuansheng venture capital and Xiamen Construction Development Group.

Mass spectrometry detection market is known as "the next 10 billion Blue Ocean after gene detection". Mass spectrometry has been widely carried out in developed countries in Europe and the United States. According to statistics, there are more than 400 mass spectrometry detection projects serving clinical diagnosis and treatment, including neonatal genetic and metabolic disease screening, hormone and metabolite detection, therapeutic drug monitoring, vitamin detection, trace element detection, etc. Compared with the United States, China's clinical mass spectrometry detection is in the early stage of development, but also the eve of the outbreak. 2018 is known as the first year of China's clinical mass spectrometry. Shandong Yingsheng is an enterprise that has been devoting to research and development in the field of mass spectrometry for many years, and is committed to popularizing high-end mass spectrometry detection and serving patients and hospitals.

Shandong Yingsheng Biotechnology Co., Ltd. was founded in 2009, located in Jinan high tech Development Zone. Since its establishment, it has been focusing on independent research and development, production and sales of in vitro diagnostic reagents and medical equipment, and has built a gene detection platform and mass spectrum detection platform around genomics and mass spectrometry, covering the fields of birth defect screening, disease prevention and human health services. At the same time, Ying Sheng has always put clinical needs first, striving to build a one-stop integrated mass spectrometry solution, providing comprehensive services and solving customer problems. Yingsheng's product line includes 45 newborn screening reagents for genetic and metabolic diseases, 14 vitamin testing reagents, automatic intelligent mass spectrometry processing platform, ultra-high performance liquid chromatography tandem mass spectrometry detection system, etc., which are independently developed, and the products have reached the international leading level.

Mr. Feng Zhen, chairman of Shandong Yingsheng, said: "Yingsheng's one-stop integrated mass spectrometry solution will make mass spectrometry the most commonly used inspection method in hospitals. Ying Sheng's goal is to make mass spectrometry a simple, convenient, fast, accurate and affordable detection method, and become the most daily partner of hospitals and patients. The mass spectrometer used in China has been heavily dependent on imports. Yingsheng has cooperated with thermofisher, a global scientific instrument giant, to localize LC-MS, ICP-MS and other high-end mass spectrometer, reduce the price threshold of mass spectrometer, and accelerate the rise of domestic high-end medical equipment manufacturing. "

The tedious sample preprocessing process has always been one of the biggest bottlenecks restricting mass spectrometry to be widely used in clinical practice. Ying Sheng, in cooperation with Swedish biotechnology and Swiss Hamilton, has developed a full-automatic preprocessing platform to hand over complex manual operations to machine automation. In terms of clinical mass spectrometry detection projects, Ying Sheng has been engaged in the research and development of 48 genetic and metabolic disease diagnoses, 14 vitamin tests, drug concentration monitoring, etc. for many years, and is about to obtain CFDA registration certificate, and has completed the research and development of multiple project packages such as fatty acid, amino acid, bile acid, etc. Yingsheng will continue to pay attention to major diseases such as tumor, cardiovascular and cerebrovascular diseases, Alzheimer's disease and diabetes, give full play to the advantages of high-throughput and high accuracy of mass spectrometry detection, and develop more clinical level detection projects. Thanks to Yuansheng venture capital and Xiamen Jianfa group for their recognition of Yingsheng. Capital from well-known investment institutions will surely push Yingsheng to a higher level.

Lin Yi, managing partner of Yuansheng venture capital, said: "mass spectrometry is the next big blue ocean market in the field of in vitro diagnosis, and Yingsheng will become the leader of the track. Mass spectrometry is expected to become the next "gene sequencing" in the in vitro diagnostic market, and it is a platform technology with a large market space. In the United States, more than 25000 independent laboratories have been approved to carry out clinical detection of CLIA mass spectrometry, with a market size of about $10 billion. However, in China, the development of clinical mass spectrometry is similar to the early stage of gene sequencing. Mass spectrometry only accounts for about 1-2% of the total medical detection market, and has great potential in the future. Technically speaking, mass spectrometry can accurately quantify tens of hundreds of markers at a time, and it is particularly suitable for the detection of small molecular substances, which can form a good complementary with the most commonly used chemiluminescence methods in hospitals. "

Yingsheng's founding teams are all from professional medical backgrounds, and have a deep understanding of the actual pain points and needs of clinical testing. Many products of the company have or will get CFDA registration certificate, covering all aspects of mass spectrometry detection, which can provide customers with "one-stop solution". As a highly professional analysis platform, mass spectrometry should be promoted in China, not only selling products, but also competing services. Yingsheng has established a professional technical service team and won good reputation among customers. It can be said that Yingsheng has a long-term layout in product R & D and international cooperation, and has a pragmatic style in sales and technical services. We believe that it will grow into a leading enterprise in the blue ocean market of mass spectrometry.

"We are very happy to invest in Shandong Yingsheng," said Ms. Shen Yaping, deputy general manager of Xiamen Jianfa emerging industry Equity Investment Co., Ltd. As a platform technology for precise diagnosis and treatment, mass spectrometry has great potential and has been widely used in the U.S. market. In China, clinical mass spectrometry is in the initial stage of rapid growth, which is a track worthy of investment. Yingsheng's management team has accumulated rich experience in the field of mass spectrometry detection, with complete detection product layout and strong sales and technical service team, which has the potential to become a leading enterprise in the field of mass spectrometry detection. Jianfa group always pays attention to the application of advanced medical technology in China to meet the clinical needs of patients to the greatest extent. "